Nano dressing as well as preparation method and application thereof
By combining the recombinant FN polypeptide with nanochitosan, a nanodress with a particle size of 60-100 nm was prepared, which solved the problems of insufficient biocompatibility of nanoparticles and large molecular weight of fibronectin, and achieved wound healing and reduced inflammation. The effect significantly improves the wound repair efficiency.
Patent Information
- Application Number
- CN202411042708.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-22
AI Technical Summary
The biocompatibility of existing nanoparticles such as inorganic silver, copper and zinc nanoparticles has limited their further development in medical applications. At the same time, the molecular weight of fibronectin is large and the physical and chemical properties are unstable, which limits its trauma repair. Application in.
Develop a nanodressing that binds recombinant FN polypeptide to nanochitosan. By constructing protein nanochitosan particles loaded with recombinant FN polypeptide, adjusting pH value and adding sodium tripolyphosphate, nanometers with particle sizes of 60-100nm were prepared. Dressing, used to promote wound healing and reduce inflammatory response.
The biocompatibility and stability of the physical and chemical properties of the nanodresses were achieved, which significantly accelerated the wound healing process, reduced the inflammatory response, and promoted the new angiogenesis of the wound.
Smart Images

Figure CN118987335A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a nano dressing and a preparation method and application thereof. Background Art
[0002] The development of highly bioactive wound dressings that can accelerate wound healing and skin regeneration is the key to clinical wound reconstruction. Chitosan (CS) is a rich natural alkaline polysaccharide, the second largest biological resource in nature after cellulose. It has good biocompatibility, biodegradability, human affinity, and excellent properties such as antibacterial, hemostasis and promotion of wound healing. It can be absorbed by itself after use, does not cause allergies, and can accelerate wound healing, protect large-area burns, and promote skin regeneration. The medical non-woven fabric produced with it can be used on burn wounds and donor areas, not only covering and protecting the wound surface, but also has low antigenicity. Therefore, chitosan biological dressings have received more and more attention in recent years and have been used in the field of biomedicine. Chitosan can be made into a variety of different materials for application, such as fibers, scaffolds and nanoparticles. Currently, the most widely used nanoparticles are inorganic silver, copper, and zinc nanoparticles, but their poor biocompatibility limits their further application in medicine. In comparison, chitosan is a product of the natural polysaccharide chitin with some acetyl groups removed. It is biodegradable, biocompatible, and non-toxic, and has obvious advantages.
[0003] At the same time, fibronectin (Fn) is a high molecular weight glycoprotein in the extracellular matrix, which mainly exists in three forms, namely plasma fibronectin produced by hepatocytes or endothelial cells, cellular fibronectin synthesized by fibroblasts and early mesenchymal cells, and fetal fibronectin in placenta and amniotic tissue. As a matrix factor with important biological functions, fibronectin plays an important role in all stages of wound repair. However, its molecular weight is too large, its physical and chemical properties are not stable, it is easily oxidized and degraded at room temperature and pressure, and it is easy to agglomerate, which limits its further development and application. Summary of the invention
[0004] The purpose of the present invention is to provide a recombinant FN polypeptide with good biocompatibility, small molecular weight and stable physical and chemical properties. The polypeptide is prepared together with nano-chitosan to prepare a nano-dressing, which has the effect of promoting wound healing and reducing inflammatory response.
[0005] To achieve the above object, the present invention provides a nano dressing comprising a recombinant FN polypeptide; the recombinant FN polypeptide comprises an amino acid sequence shown in SEQ ID NO:1.
[0006] Furthermore, the preparation method comprises the following steps: adding nano-chitosan and acetic acid to ultrapure water to obtain a first solution, adjusting the pH to acidic, filtering to obtain a filtrate, adding recombinant FN polypeptide to the filtrate to obtain a mixed solution containing protein nano-chitosan particles; stirring the mixed solution and dripping sodium tripolyphosphate solution thereto to obtain a second solution; centrifuging the second solution to obtain a precipitate; and resuspending the precipitate by blowing to prepare a nano-dressing.
[0007] Further, adjusting the pH to acidic is adjusting the pH to 4.5-5.0; and / or
[0008] The particle size of the protein nano-chitosan particles is 60-100 nm; and / or
[0009] The mass ratio of recombinant FN polypeptide, nano-chitosan and sodium tripolyphosphate is 0.5-1.5:5:4.
[0010] Furthermore, the nano dressing has the purpose of promoting wound healing.
[0011] Furthermore, the nano-dressing has the use of reducing inflammatory response.
[0012] In the present invention, the functional domain in fibronectin (FN) is selected to reduce its molecular weight, but retain its function of promoting cell migration and adhesion, thereby obtaining a recombinant FN polypeptide. The coding gene of the recombinant FN polypeptide is combined with an Escherichia coli expression vector to construct a recombinant FN protein expressing 23.5 kd, with a considerable expression amount and good biological activity.
[0013] The present invention also combines recombinant FN polypeptide with chitosan to construct protein nano-chitosan particles loaded with recombinant FN polypeptide to prepare nano-dressings. The nano-dressings have been verified by animal full-thickness wound experiments, and the experimental results show that the nano-dressings have the ability to accelerate angiogenesis, reduce inflammatory reactions and promote wound healing. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 is the plasmid map of the expression vector in Example 1 of the present invention;
[0015] Figure 2 The SDS-PAGE electrophoretogram in Example 1 of the present invention is shown;
[0016] Figure 3 This is a light microscopic image of cell scratches in Example 2 of the present invention;
[0017] Figure 4 This is a data analysis diagram of the cell scratch experiment in Example 2 of the present invention;
[0018] Figure 5 It is the crystal violet staining diagram in Example 2 of the present invention;
[0019] Figure 6 This is a biocompatibility data analysis diagram in Example 2 of the present invention;
[0020] Figure 7 This is a particle size characterization diagram of the protein nano-chitosan particle biomaterial in Example 3 of the present invention;
[0021] Figure 8 This is a size diagram of the mouse wound surface in Example 4 of the present invention;
[0022] Fig. 9 This is a heat map of the wound size of mice in Example 4 of the present invention;
[0023] Fig.10 This is a graph showing the wound healing data of mice in Example 4 of the present invention;
[0024] Fig.11 This is the HE staining image of the mouse back wound sample in Example 4 of the present invention;
[0025] Fig.12 This is a graph showing double fluorescence staining of mouse wound samples and expression analysis of CD31 and α-SMA in Example 4 of the present invention;
[0026] Fig.13 This is a graph showing the gene expression analysis of a small number of wound samples in Example 4 of the present invention. DETAILED DESCRIPTION
[0027] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limitations of the present invention. Those who do not indicate specific techniques or conditions in the embodiments are carried out according to the techniques or conditions described in the literature in this area or according to the product specification. Those who do not indicate the manufacturer of the reagents or instruments used are all conventional products that can be obtained commercially. In the following embodiments, if not clearly stated, "%" refers to weight percentage.
[0028] 1. Solid screening medium: containing 100 μg / ml ampicillin; weigh 10g of tryptone, 5g of yeast extract, 10g of sodium chloride (NaCl), add 15g of agar, add 1000mL of water and stir evenly, sterilize at 121℃ for 20min, place the melted LB solid medium in a 55℃ water bath, and add ampicillin when the temperature of the medium drops to 55℃ (touchable) to prevent the antibiotic from becoming ineffective due to excessive temperature, shake well, and pour the plate for later use.
[0029] 2. Liquid culture medium: containing 100 μg / ml ampicillin; weigh 10 g of tryptone, 5 g of yeast extract, and 10 g of sodium chloride (NaCl), add 1000 mL of water and stir evenly, heat to dissolve and then divide into portions, sterilize at 121°C for 20 min, cool to below 50°C and add ampicillin.
[0030] 3. The data analysis in the examples of the present invention were all performed using Image J software. * indicates P < 0.05, *** indicates P < 0.001, **** indicates P < 0.0001, and ns indicates no significant difference.
[0031] Example 1: Recombinant FN polypeptide and preparation method thereof
[0032] (1) The nucleic acid encoding the recombinant FN polypeptide was fully synthesized, and the nucleic acid was connected to the vector pET-22b (the vector was purchased from Shanghai Newpro) by double digestion with XbaI / BIpI to obtain a recombinant expression vector, which was transformed into a host cell to obtain the first recombinant. The host cell was an E. coli BL21 (DE3) competent cell; the plasmid map of the vector is shown in FIG. Figure 1 shown.
[0033] (2) The obtained first recombinant was inoculated into a solid screening medium and cultured at 37°C overnight to obtain a positive clone.
[0034] (3) Place the positive clones in liquid culture medium and culture at 37°C until the OD 600 When the value is 0.5, the seed solution is prepared; the seed solution is inoculated into the liquid culture medium at a ratio of 1:100 (v / v), and after shaking culture at 37°C for 7 hours, a mutagen with a final concentration of 0.1M is added, and the expression is induced by shaking culture overnight at 28°C, and the bacteria obtained by induced expression are collected by centrifugation; the mutagen is isopropyl β-D-thiogalactoside (IPTG).
[0035] (4) Resuspend the cells at a ratio of 5 ml of lysis buffer to 1 g of cells, add 100 mM phenylmethylsulfonyl fluoride (PMSF) and ultrasonically disrupt the cells for 40 min. After the cells are completely disrupted, transfer them to a centrifuge tube and centrifuge them at 12,000 rpm for 15 min at 4°C. After centrifugation, retain the first supernatant and filter the first supernatant using a 0.45 μm filter membrane to obtain a crude protein extract.
[0036] (5) Purify the crude protein extract using a His-tag denaturation-resistant nickel column, wash the impurities with a washing solution, and finally collect the target protein with an eluent to obtain a target protein solution.
[0037] (6) Use Triton X-114 to remove endotoxin in the target protein solution. Add 1% Triton X-114 to the target protein solution, shake well and place at 4°C for 30 minutes, heat in a 37°C water bath for 30 minutes, centrifuge at 12000 rpm for 15 minutes at 37°C, collect the second supernatant, and then desalt the second supernatant using a G25 dextran gel column. Determine its protein concentration using a BCA protein concentration kit. Finally, filter the resulting protein solution through a 0.22 μm filter membrane to obtain the recombinant FN polypeptide, package it according to the needs, and store it at -20°C.
[0038] The amino acid sequence of the recombinant FN polypeptide of the present invention is shown in SEQ ID NO: 1, and the nucleotide sequence of the gene encoding the recombinant FN polypeptide is shown in SEQ ID NO: 2.
[0039] The recombinant FN polypeptide contains the amino acid sequence shown in SEQ ID NO: 1:
[0040] MTPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNASYTIKGLKPGPFSPLVATSEDVPRDLEVVAVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPV SEQID NO:1.
[0041] The nucleotide sequence encoding the recombinant FN polypeptide contains the nucleic acid sequence shown in SEQ ID NO: 2:
[0042] ; SEQ ID NO:2.
[0043] The recombinant FN polypeptide prepared in the above steps was subjected to SDS-PAGE electrophoresis analysis. The electrophoresis detection results are shown in Figure 2 As shown, lane M is a marker, and samples in lanes 1, 2, 3, and 4 are prepared recombinant FN polypeptides, whose bands are around 25 KDa and have high purity and concentration.
[0044] Example 2: Functional verification experiment of recombinant FN polypeptide
[0045] 1. Cell scratch test of recombinant FN polypeptide:
[0046] In this example, L929 mouse fibroblasts were used to perform a cell scratch experiment to explore the effect of the recombinant FN polypeptide on cell migration. The specific steps are as follows:
[0047] (1) Marking: First, use a marker to mark the back of the six-well plate, drawing 3-5 lines in each well.
[0048] (2) Plating: After adjusting the cell state, the cells are plated. The density of the plating needs to be adjusted appropriately according to the growth characteristics of the cells themselves. For L929 cells, 6×10 5 cells.
[0049] (3) Scratching: When the cells have spread into a monolayer, use a 10 μL pipette tip close to a ruler to draw a line in the well perpendicular to the horizontal line marked by the marker. Try to ensure that each scratch is consistent. It is best to use the same pipette tip to scratch different wells. When scratching, the pipette tip should be vertical and not tilted. Use a ruler to maintain consistent force and complete the scratching in one go.
[0050] During the scratch test, the cells were cultured in serum-free medium, which can reduce the effect of simple cell proliferation on migration. After scratching the surface of the 6-well plate cells with a pipette tip, the non-adherent cells were washed with PBS, and then 10μl of the following concentrations of recombinant FN polypeptide were added to different experimental groups: 5μg / ml, 10μg / ml, and 50μg / ml. (At the same time, a control group was set up, and the recombinant FN polypeptide was replaced with an equal volume of PBS).
[0051] (4) Image acquisition: Use a fluorescent inverted microscope to take pictures at different time points to ensure that the scratch is centered. Figure 3 As shown, the dotted line shows the boundary of the scratch; 0 μg / ml FN represents the Control group, and 5 μg / ml FN, 10 μg / ml FN, and 50 μg / ml FN represent experimental groups with recombinant FN polypeptide concentrations of 5 μg / ml, 10 μg / ml, and 50 μg / ml, respectively.
[0052] Image J software was used to analyze the scratch area, with time as the horizontal axis and migration rate as the vertical axis to present the results. Figure 4 As shown, there are 5 data bars at each time point on the horizontal axis, and the concentrations of the recombinant FN polypeptide used are 0 μg / ml, 5 μg / ml, 10 μg / ml, and 50 μg / ml from left to right.
[0053] The results of the scratch area analysis using Image J software indicate that the recombinant FN polypeptide provided by the present invention can significantly promote the migration of L929 mouse fibroblasts and accelerate the healing of scratches. Figure 3 Schematic diagram of the scratch test and Figure 4From the scratch experiment data analysis chart, it can be seen that the cell scratches in cells treated with different concentrations of recombinant FN polypeptide have different degrees of recovery. Compared with the control group, in which cells were not treated with recombinant FN polypeptide, the area of cell scratches in cells treated with recombinant FN polypeptide was significantly reduced within the same treatment time.
[0054] 2. Cell adhesion assay of recombinant FN polypeptide:
[0055] In this example, L929 mouse fibroblasts were used to conduct a cell adhesion experiment to explore the adhesion ability of the recombinant FN polypeptide to cells. The specific steps are as follows:
[0056] (1) Coating culture plates: Add 10 μl of the following recombinant FN polypeptide concentrations according to different experimental groups: 1 μg / ml, 5 μg / ml, 10 μg / ml, 50 μg / ml. Set up a control group in which the recombinant FN polypeptide is replaced with an equal volume of PBS); coat the 96-well plate at 4°C overnight.
[0057] (2) BSA immersion: aspirate the coating solution, add 200 μl of heat-denatured 1% BSA (BSA is heat-denatured at high temperature and high pressure after preparation), and incubate the 96-well plate at 37°C for 1 hour.
[0058] (3) Washing with culture medium: Wash the 96-well plate twice with serum-free culture medium.
[0059] (4) Preparation of cell suspension: L929 cells were digested with trypsin containing EDTA, and then digestion was terminated with serum-containing medium. Finally, the cells were washed and resuspended in serum-free medium.
[0060] (5) Plate: After counting the cell suspension, plate the cell suspension in a pre-treated 96-well plate, with 3-5×10 4 cells.
[0061] (6) Continue culturing: Incubate the 96-well plate in a cell culture incubator for 4 h.
[0062] (7) Wash off non-adherent cells: Wash the cultured 96-well plate three times with PBS.
[0063] (8) Crystal violet staining: Add 1% crystal violet to a 96-well plate and incubate for 20 min, then wash 3-4 times with PBS.
[0064] The stained samples were photographed and observed under a fluorescent inverted microscope. Figure 5 As shown, Figure 5 A is a schematic diagram of the crystal violet staining results of cells. Figure 5B is a cell adhesion data analysis chart. In the absence of the addition of recombinant FN polypeptide, the cells are spherical, not spread out, and the number of adhered cells is very small. After the addition of the recombinant FN polypeptide, the cells show a more complete cell morphology, in the form of filaments. At the same time, according to the calculation of the number of cells in the randomly selected field of view, it was found that the number of adhered cells in the experimental groups with recombinant FN polypeptide concentrations of 5μg / mL, 10μg / mL and 50μg / mL was significantly different from that in the control group (FN3 in the figure is equivalent to the recombinant FN polypeptide in the present invention).
[0065] The adhesion ability of cells treated with different concentrations of recombinant FN polypeptides was different. Compared with the control group in which cells were not treated with recombinant FN polypeptides, cells treated with different recombinant FN polypeptides all had better adhesion ability.
[0066] 3. Biocompatibility test:
[0067] (1) Select L-929 cells with good growth status. When the cell density grows to between 80% and 90%, remove the old culture medium with a pipette, rinse with PBS three times, add 1 mL of trypsin to the cell culture dish, and then incubate the dish in a 37°C incubator for 1 min.
[0068] (2) Remove the cells from the incubator, add 2 mL of complete culture medium (1% double antibody-penicillin-streptomycin mixture, 10% fetal bovine serum, 89% MEMα culture medium) to terminate digestion, gently pipette, add the cell suspension to a 2 mL centrifuge tube, and centrifuge at 1000 × g for 5 min to remove trypsin;
[0069] (3) Resuspend the cells in 2 mL of complete culture medium, pipette 20 μL of the cell suspension into a cell counting plate, and determine the cell number using a cell counter;
[0070] (4) Dilute the cells to a concentration of 3 × 10 per well. 3 Each cell number was added into a 96-well plate, and 200 μL of PBS was added to the edge of the 96-well plate to reduce the influence of water evaporation on the experiment;
[0071] (5) After the cells were cultured in a 37°C constant temperature incubator for 24 h, complete culture medium containing 1, 5, 10, and 50 μg / mL recombinant FN polypeptide was added to the experimental group, and complete culture medium without recombinant FN polypeptide was added to the control group;
[0072] (6) A 96-well plate was taken out at different time periods, and 10% solution volume of CCK-8 solution was added to each well, followed by incubation in a 37°C incubator for 90 min. The absorbance at 450 nm was measured using an enzyme reader.
[0073] according to Figure 6 It can be seen that the nano dressing containing protein nano chitosan particles of different concentrations prepared by the method of Example 3 of the present invention was co-cultured with L929 cells, and it can be concluded that the nano dressing proposed in the present invention has good biocompatibility (FN3 in the figure is equivalent to the recombinant FN polypeptide in the present invention).
[0074] Example 3: Preparation method of nano dressing
[0075] (1) Add nano-chitosan and acetic acid to ultrapure water to obtain a first solution, add 1 mol / L sodium hydroxide to the first solution to adjust the first solution to acidity, pH 4.8, so that the concentration of chitosan in the solution is 1 mg / mL, and the concentration of acetic acid is 2 mg / mL, and stir and heat to 40°C to quickly dissolve the chitosan, and filter through a 0.45 μm filter to obtain a filtrate. Add recombinant FN polypeptide to the filtrate so that the concentration of the recombinant FN polypeptide in the solution is 10 μg / ml, and prepare 1 L of a mixed solution containing protein nano-chitosan particles.
[0076] (2) The mixed solution was stirred, and 300 ml of a 0.8 mg / mL sodium tripolyphosphate solution was added dropwise at a rate of 0.8 mL / min. The stirring time was 20 min, and the rotation speed was 750 rpm to obtain a second solution; the second solution after the reaction was completed was then centrifuged at a rotation speed of 40,000 rpm.
[0077] (3) The precipitate was resuspended by blowing with 2 mL of PBS to prepare a dispersion containing protein nano-chitosan particles, which was stored at 4° C. for future use.
[0078] The particle size scatterometer characterizes the particle size, and the results are as follows Figure 7 As shown, Figure 7 A. Figure 7 B and Figure 7 C is the particle size of protein nano-chitosan particles in the dispersion under different magnifications using transmission electron microscopy. Figure 7 D is the particle size of the protein nano-chitosan particles. The average particle size of the protein nano-chitosan particles in Example 3 of the present invention is 72.9 nm. They are well dispersed in the dispersion liquid, have a smooth surface, and have a core-shell structure.
[0079] Example 4: Functional verification of nano dressing
[0080] Female ICR mice (6-8 weeks old) weighing between 20-25g were selected, a total of 24 mice. Before the experiment, all animals rested for 7 days to adapt to the environment. The back of the mouse was depilated, and a circular wound with a diameter of 7mm was created on the back of the mouse with a circular biopsy punch. The depth and full-thickness of the skin were not damaged, and the subcutaneous fascia layer was not damaged; the normal group was only depilated, and the position was marked with a marker pen, and no modeling was performed.
[0081] After modeling, according to the experimental grouping information, the normal group and the Control group only used PBS to apply the entire wound surface, the CS nano group used CS nano for application, and the FN-CS nano group applied 10 μg / ml FN-CS nano, twice a day, 100 μL each time, and covered with sterile gauze after each application (CS nano is nano-chitosan, and FN-CS nano is the nano dressing in Example 3).
[0082] The wounds of mice were photographed at 0, 5, 8, and 10 days after modeling, and the wound area was measured. Three mice in each group were killed at 5 and 10 days, and 3 mm tissue (20 mg) from the wound edge was quickly frozen in liquid nitrogen for gene expression regulation verification. The remaining wound tissue was paraffin-embedded and HE stained to observe the tissue pathology. α-SMA and CD31 in the samples were immunofluorescently double-stained to observe the formation of new blood vessels.
[0083] 1. Analysis of wound healing degree: Figure 8 The results showed that compared with the Control group and CS nano group, the wound area of the FN-CSnano group mice was significantly reduced on the 5th day, which was visibly reduced.
[0084] At the same time, infrared thermal images of the wounds of mice were performed, such as Fig. 9 As shown. Fig. 9 It can be found that the wound surface of mice in the FN-CS nano group was significantly reduced on Day 5, basically healed on Day 8, and completely healed on Day 10. Compared with the FN-CS nano group, the wound surface of mice in the Control group and CS nano group was still partially unhealed on Day 10.
[0085] Fig.10 Used to characterize the degree of wound healing of the three groups of mice, it can be seen that the wound healing rate of the FN-CS nano group of mice is always higher than that of the Control group and the CS nano group of mice, so the nano dressing of the present invention has the effect of promoting wound healing.
[0086] Combination Figure 8 , Fig. 9 , Fig.10It can be found that the protein nano-chitosan particles proposed in the present invention have a good wound healing effect.
[0087] 2. Inflammation analysis experiment: The wound tissue of mice was embedded in paraffin and the pathological condition of the tissue was observed by HE staining. The results are as follows Fig.11 As shown. Fig.11 As shown, under a fluorescence microscope, it can be observed that on the 5th day, the skin tissue of the mice in the Control group was disordered, the epidermis was hyperplastic, the number of hair follicles was reduced, and a large number of inflammatory cells appeared. After 10 days, the epidermis of the mice in the Control group was thickened, and inflammatory cells infiltrated in the dermis; after treatment, the inflammatory cell infiltration of the CS nano group and the FN-CS nano group was significantly improved, the skin tissue structure was clear, and the FN-CS nano group was more similar to normal skin tissue. Therefore, it can be shown that the protein nano chitosan particles in the present invention have the effect of reducing the occurrence of inflammatory reactions in damaged skin, and do not cause the problem of epidermal thickening, which can better repair the wound surface and reduce the generation of epidermal scars.
[0088] 3. Wound angiogenesis: CD31 is a transmembrane protein that is mainly expressed during the early development of blood vessels. Its expression can be used to evaluate new blood vessels. α-SMA is present in the blood vessel wall and various tissue matrices. α-SMA is expressed in myofibroblasts and myoepithelial cells. It is a marker protein of myofibroblasts and plays a key role in wound healing and angiogenesis. CD31 and α-SMA can be used to evaluate the amount of new blood vessels generated. CD31 and α-SMA in the wound surface were stained by immunofluorescence, and the expression of CD31 and α-SMA was analyzed in combination with Image J. The results are as follows: Fig.12 As shown, Fig.12 A is the double fluorescence staining result of the wound sample on the 5th day of wound healing. Fig.12 B is the double fluorescence staining result of the wound sample on the 10th day of wound healing. Fig.12 C is the expression analysis of CD31 in wound samples. Fig.12 D is the expression analysis of α-SMA in wound samples.
[0089] from Fig.12 It can be seen that the fluorescence intensity and expression of CD31 and α-SMA in the wound tissue of the mice in the FN-CS nano group are higher than those in the Control group and the CS nano group, indicating that the amount of new blood vessels generated in the wound of the mice in the FN-CS nano group is greater, and the new capillaries can provide nutrition for the granulation tissue formed on the wound surface, which is more conducive to the growth and maturation of the granulation tissue on the wound surface into fibrous connective tissue, so that the wound surface heals. Therefore, the nano dressing in Example 3 can promote the generation of new blood vessels in the wound surface during the wound repair process and accelerate the recovery of normal function of the wound tissue.
[0090] 4. Expression of related genes:
[0091] During the wound healing process, granulation tissue is generated on the wound surface. Granulation tissue is a new immature fibrous connective tissue rich in capillaries. The formation of granulation tissue on the wound surface is often accompanied by the infiltration of inflammatory cells. The inflammatory cells are often dominated by macrophages, and there are also varying numbers of neutrophils and lymphocytes. Therefore, granulation tissue has anti-infection function.
[0092] Mouse tissue RNA was extracted by trizol method, cDNA was synthesized by using Novozyme reverse transcription kit, and Ct value was measured by fluorescence quantitative PCR instrument. Graph was used as internal reference gene, and according to formula 2 -ΔΔCt The relative expression levels of TNF-α, 1L-1β, PDGF and VEGF genes were converted. Fig.13 As shown, Fig.13 A is the mRNA expression level of IL-1β in wound samples on the 5th and 10th days, Fig.13 B is the mRNA expression of TNF-α in wound samples on days 5 and 10. The mRNA expression of TNF-α and IL-1β in the FN-CS nano group was significantly lower than that in the control group, which was similar to the results of H&E staining.
[0093] At the same time, the levels of TNF-α and 1L-1β also changed. Compared with the samples in the Control group and the CS nano group, the inflammatory-related factors secreted by inflammatory cells in the FN-CS nano group were lower, indicating that the nano dressing of the present invention has the effect of reducing the inflammatory response during the wound healing process.
[0094] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.
Claims
1. A nano dressing, characterized in that: Contains a recombinant FN polypeptide; the recombinant FN polypeptide contains the amino acid sequence shown in SEQ ID NO:
1.
2. The nano dressing according to claim 1, characterized in that: The preparation method comprises the following steps: adding nano-chitosan and acetic acid to ultrapure water to obtain a first solution, adjusting the pH to acidic, filtering to obtain a filtrate, adding recombinant FN polypeptide to the filtrate to obtain a mixed solution containing protein nano-chitosan particles; stirring the mixed solution and dripping a sodium tripolyphosphate solution thereto to obtain a second solution; centrifuging the second solution to obtain a precipitate; and blowing and resuspending the precipitate to prepare a nano-dressing.
3. The nano dressing according to claim 2, characterized in that: The adjusting pH to acidic is adjusting the pH to 4.5-5.0; and / or The particle size of the protein nano-chitosan particles is 60-100 nm; and / or The mass ratio of the recombinant FN polypeptide, nano-chitosan and sodium tripolyphosphate is 0.5-1.5:5:
4.
4. The nano dressing according to claim 1 has the purpose of promoting wound healing.
5. The nano dressing according to claim 1 has the purpose of reducing inflammatory response.
Citation Information
Cited By
Recombinant FN polypeptide, product containing polypeptide and preparation method of product
CN118955687A
